Stem Cell Clinic

Drugs that trip cellular alarm could help clear out hibernating HIV – New Atlas

By Stem Cell Medicine

HIV can currently be managed with a lifelong daily drug regimen, but unfortunately the infection cant be eliminated entirely. Now, researchers have found a potential way to trip a cellular alarm to alert the immune system to clear out infected cells.

An HIV diagnosis is no longer a death sentence antiretroviral therapy (ART) can prevent the virus from replicating and spreading, letting patients live mostly normal lives. But the virus still lurks inside infected cells, ready to spring into action if the daily drug treatment is ever interrupted.

However, recent work has raised hopes that HIV might be completely curable in the not-too-distant future. Various studies have shown promise in ripping the virus from its hideout using kick and kill drug combos, immunotherapy, engineered stem cells, genetic kill switches, CRISPR gene-editing, or CRISPR and ART drugs together.

In the new study, researchers from Washington University in St. Louis identified a promising new method. They found that human immune cells have an alarm system called the CARD8 inflammasome, which detects a protein called HIV protease and marks the infected cell for destruction.

The problem is, HIV is crafty and it knows how to avoid detection. It silences that protein while inside cells, and usually only activates it once it leaves immune cells, where CARD8 cant reach it.

So for the new study, the researchers found a way to activate that protein while the virus is still inside the cell, where CARD8 can detect it and alert the immune system to destroy the infected cell. Using this method, HIV could be dragged out of hiding and eliminated from a patient entirely. Better yet, one of the drugs that makes HIV protease active again is efavirenz, an antiretroviral drug already in use for HIV.

Weve long used this class of drugs to block HIV from inserting its genetic material into new cells, says Liang Shan, senior author of the study. Thats their day job. But now, we have learned they have a second job activating HIV protease inside the infected cell. When we treat HIV-infected human T cells with this drug, the protease becomes activated before the virus successfully leaves the infected cells. This triggers the CARD8 inflammasome, and the infected cells die within hours. This is a potential route to clearing the virus that we have never been able to completely eliminate.

In tests in human cells in culture, the team showed that the technique worked to destroy the infected cells. It even worked against a range of HIV subtypes found around the world.

Of course, its still early days for the study, and theres no guarantee that the results would carry across to humans. Tests in animals will likely follow, before any trials in humans are conducted, but the method is another intriguing potential tool to add to our growing arsenal against HIV.

The research was published in the journal Science.

Source: Washington University in St. Louis

Read the original post:
Drugs that trip cellular alarm could help clear out hibernating HIV - New Atlas

Responses to Liso-Cel Not Influenced by Prior Treatment With Anti-CD19 Agents in R/R Large B-Cell Lymphoma – Targeted Oncology

By Stem Cell Medicine

A post-hoc analysis of the practice-changing TRANSCEND NHL 001 trial (NCT02631044) revealed that exposure to anti-CD19 therapy in patients with relapsed/refractory large B-cell lymphoma (LBCL), did not impact response to lisocabtagene maraleucel (liso-cel; Breyanzi).1

Data were presented during the 2021 Transplantation & Cellular Therapy Meeting and showed that among 12 patients who had previously received anti-CD19 therapy, 2 patients achieved a complete response (CR) as their best response to that treatment, 3 patients reported a partial response (PR), and 1 achieved stable disease. Five patients experienced disease progression, while 1 patients response status was unknown.

Results from the analysis showed that 92% (n = 11/12) experienced an objective response to liso-cel per independent review committee (IRC) assessment and Lugano criteria; this included 6 CRs (50%) and 5 PRs with the CAR T-cell therapy. Moreover, 5 patients experienced a duration of response (DOR) to liso-cel of 9 months or longer (range, 0.8-27.4), with 4 patients continuing to respond at the time of data cutoff.

The response rates reported in this subgroup proved to be comparable to those observed in the overall TRANSCEND NHL 001 study population. Of the 256 patients determined to be efficacy evaluable, which included those who were given at least 1 dose of liso-cel and had PET-positive disease per IRC, the objective response rate was 73% (95% CI, 66.8%-78.0%), with a CR rate of 53% (95% CI, 46.8%-59.4%).2 The median DOR had not been reached (95% CI, 8.6not reached [NR]). Moreover, the median progression-free survival (PFS) was 6.8 months in this population (95% CI, 3.3-14.1) and the median overall survival (OS) was 21.1 months (95% CI, 13.3-NR).

In this post-hoc analysis of a small subset of patients from TRANSCEND, patient response to liso-cel and liso-cel pharmacokinetics were not impacted by prior exposure to anti-CD19 therapy, Scott R. Solomon, MD, of the Blood and Marrow Transplant Program, Leukemia and Cellular Immunotherapy Program at the Northside Hospital Cancer Institute, and colleagues, wrote in a poster highlighting the data. Additional analyses on a larger number of patients with prior anti-CD19 therapy are warranted to confirm these findings.

An investigational, CD19-targeted, defined composition, 4-1BB CAR T-cell product, liso-cel is given at equal target doses of CD8 and CD4 T cells; the product has showcased safety and efficacy in patients with aggressive, relapsed/refractory LBCL in the TRANSCEND NHL 001 trial. Data from the trial led to theFebruary 2021 FDA approval of liso-cel for use in adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least 2 other types of systemic treatment.

The multicenter, pivotal, phase 1 trial enrolled adult patients aged 18 years or older with relapsed/refractory LBCL; this included those with diffuse large B-cell lymphoma (DLBCL); high-grade B-cell lymphoma with rearrangements of MYC and either BCL-2, BCL-6, or both; DLBCL transformed from an indolent lymphoma; primary mediastinal B-cell lymphoma; and follicular lymphoma. To be eligible for enrollment, patients had to have an ECOG performance status of 0-2, creatinine clearance of greater than 30 mL/min/1.73 m2, and a left ventricular ejection fraction of at least 40%.

Those who underwent prior hematopoietic stem cell transplantation and those with secondary central nervous system lymphoma were permitted. Notably, no lower threshold for absolute lymphocyte count, absolute neutrophil count, platelets, or hemoglobin, were established.

In the trial, patients were screened and then underwent leukapheresis where bridging therapy was permitted while the product was being manufactured. Once disease was reconfirmed via PET imaging, patients went on to receive lymphodepleting chemotherapy with fludarabine at 30 mg/m2 and cytarabine at 300 mg/m2, delivered over the course of 3 days. Two to 7 days after the chemotherapy, patients received liso-cel.

A total of 269 participants were assigned to 1 of 3 target dose levels of the CAR T-cell product: 50 106 CAR T cells (1 or 2 doses), 100 106, and 150 106; this was given as a sequential infusion of 2 components, CD8 and CD4 CAR T cells, at equal target doses.

The co-primary end points of the trial included adverse effects (AEs), dose-limiting toxicities, and ORR per Lugano criteria and IRC. Key secondary end points comprised CR rate by IRC, DOR, PFS, OS, and cellular kinetics.

For the post-hoc analysis, investigators looked at a subset of patients from the trial who had previously received CD19-targeted therapy before liso-cel to evaluate impact of the CAR T-cell product on safety and efficacy outcomes, as well as cellular kinetics.

The median age of the 12 patients in the subgroup of interest was 60.5 years, and 83% were male. Half of the patients had an ECOG performance status of 0, while the remainder had a status of 1. The median number of previous lines of treatment was 4. Fifty-eight percent of patients previously underwent transplantation and 67% were refractory to chemotherapy. Regarding histology, 58% had DLBCL not otherwise specified, 33% had DLBCL that was transformed from follicular lymphoma, and 8% had high-grade B-cell lymphoma.

Additional data showed that previous anti-CD19 therapy did not impact cellular kinetic parameters. Liso-cel demonstrated long-term persistence at 3 months in the majority, or 83% (n = 5/6), of those who received prior CD19-targeted treatment; persistence at 1 year was observed in 50% of patients (n = 2/4), which was comparable to those who did not receive previous CD19-targeted treatment.

Regarding safety, all patients in this subgroup experienced treatment-emergent AEs (TEAEs), 58% (n = 7) of which were grade 3 or higher. The most reported grade 3 or higher TEAEs included neutropenia (58%), thrombocytopenia (42%), and anemia (33%). Sixty-seven percent of patients reported all-grade cytokine release syndrome (CRS) and 42% experienced all-grade neurological effects with liso-cel. However, all toxicity rates proved to be comparable to those experienced by the overall study population and all CRS or neurological effects were either grade 1 or 2.

These findings suggest that liso-cel can be considered for the treatment of patients who have received prior anti-CD19 therapies, concluded Solomon.

References:

1. Solomon S, Mehta A, Abramson JS, et al. Experience of prior anti-CD19 therapy in patients with relapsed or refractory large B-cell lymphoma receiving lisocabtagene maraleucel (liso-cel), an investigational anti-CD19 chimeric antigen receptor T cell product. Presented at: 2021 Transplantation & Cellular Therapy Meeting; February 9-13, 2021; Virtual.

2. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-0

Read the rest here:
Responses to Liso-Cel Not Influenced by Prior Treatment With Anti-CD19 Agents in R/R Large B-Cell Lymphoma - Targeted Oncology

Hemophilia Treatment Market Analysis to 2025 – Growth Trends and Changes Influencing the Industry – Technology Magazine

By Gene Therapy Clinics

Global hemophilia treatment market is inclined to accumulate substantial returns over the ensuing years owing to the rising cases of genetic abnormalities and increasing prevalence of hemophilia. Hemophilia is a rare bleeding disorder, which causes incessant or prolonged bleeding after an injury or surgery due to delayed blood clotting. Quality care and efficient treatment can help prevent some serious consequences of the disorder.

Development of advanced treatment technologies such as hemophilia gene therapy is slated to further augment market growth in the succeeding years. Biotechnology companies have been particularly proactive in this regard, working on investigational gene therapies for patients with severe hemophilia A. Successful execution and approval of hemophilia gene therapy will have a substantial effect on hemophilia treatment market size in the future.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2772

Based on product, the recombinant factor concentrates segment is poised to exhibit a growth rate of 5% through 2025, as a result of low disease transmission risks and its prevention of viral infection. Additionally, the product is capable of increasing the replacement therapy safety.

The global hemophilia treatment market from the adult segment recorded revenue worth $6,778.2 million in 2018, as adult patients have high chances of developing moderate to severe hemophilia. As per authentic reports, over 65% of the patients diagnosed with hemophilia are adults.

With regards to the treatment spectrum, the global hemophilia treatment market from the prophylaxis treatment segment registered remuneration of $7,219.9 million in 2018 and is set to account for a major market share over the forecast spell, which can be credited to its effectiveness in treating bleeding episodes and joint pain.

Based on end-use, the hemophilia treatment centers segment is poised to register a growth rate of 4.6% through 2025, which can be attributed to the enhanced care services provided by these centers as compared to clinics and hospitals.

Major industry players have executed several growth strategies such as collaborations, new launches, and mergers to reinforce their position in the global hemophilia treatment market. In 2017, patients with hemophilia A received a more long-lasting option with Roches Hemlibra. The drug received approval from Health Canada for hemophilia A patients deprived of factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce its frequency. Increasing demand for Roches Hemlibra and similar medications among hemophilia A patients would escalate hemophilia treatment industry share.

The competitive landscape of the hemophilia treatment market comprises of companies such as Genentech, Biotest AG, Swedeish Orphan Biovitrum AB, and Sanofi SA, among others. These firms are focusing on expanding their stance in the global market through various strategies including partnerships and innovative product launches.

Request for customization @ https://www.gminsights.com/roc/2772

Partial Chapter of the Table of Content

Chapter 5. Hemophilia Treatment Market, By Product

5.1. Global market share by product, 2018 & 2025

5.2. Recombinant Factor Concentrates

5.2.1. Market size, by region, 2014 2025 (USD Million)

5.2.2. Factor VIII

5.2.2.1. Market size, by region, 2014 2025 (USD Million)

5.2.3. Factor IX

5.2.3.1. Market size, by region, 2014 2025 (USD Million)

5.3. Plasma-derived Factor Concentrates

5.3.1. Market size, by region, 2014 2025 (USD Million)

5.3.2. Factor VIII

5.3.2.1. Market size, by region, 2014 2025 (USD Million)

5.3.3. Factor IX

5.3.3.1. Market size, by region, 2014 2025 (USD Million)

5.4. Extended Half-life Products

5.4.1. Market size, by region, 2014 2025 (USD Million)

5.4.2. Factor VIII

5.4.2.1. Market size, by region, 2014 2025 (USD Million)

5.4.3. Factor IX

5.4.3.1. Market size, by region, 2014 2025 (USD Million)

5.5. Others

5.5.1. Market size, by region, 2014 2025 (USD Million)

Browse full table of contents (TOC) of this report @ https://www.gminsights.com/toc/detail/hemophilia-treatment-market

Read this article:
Hemophilia Treatment Market Analysis to 2025 - Growth Trends and Changes Influencing the Industry - Technology Magazine

Alpha Thalassemia Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 NeighborWebSJ – NeighborWebSJ

By Gene Therapy Clinics

Alpha Thalassemia Market Forecast 2020-2027

The Global Alpha Thalassemia Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Alpha Thalassemia Market during the forecast period between 2020 and 2027. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/39552

The Report Covers the Following Companies: Bluebird Bio Novartis Kiadis Pharma Acceleron Pharma

By Types: Iron Chelating Drugs Gene Therapy

By Applications: Hospitals Private clinics Other

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/39552

Years Considered to Estimate the Market Size: History Year: 2015-2020 Base Year: 2020 Estimated Year: 2020 Forecast Year: 2020-2027

Important Facts about Alpha Thalassemia Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/39552

About UpMarketResearch: Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearch Name Alex Mathews Email [emailprotected] Organization UpMarketResearch Address 500 East E Street, Ontario, CA 91764, United States.

https://neighborwebsj.com/

Here is the original post:
Alpha Thalassemia Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 NeighborWebSJ - NeighborWebSJ

Creative Bioarray Offers Stem Cell Lines Generation Service for Promoting Scientific Research – Press Release – Digital Journal

By Adult Stem Cells

Recently, Creative Bioarray announced the release of its stem cell line generation services in order to promote scientific research.

New York, USA - February 9, 2021 - Creative Bioarray, the world's leading biotechnology company focuses on offering high quality products and services including cell services, biosample services and histology services to accelerate life science research, help scientists solve complex analytical issues. Recently, Creative Bioarray announced the release of its stem cell line generation services in order to promote scientific research.

At present, stem cell research and application are focused on adult stem cells and iPSC, which is a technology called "reprogramming" to develop stem cells from somatic cells. Therefore, generating stem cell lines from different sources through different methods to maintain the high purity and viability of stem cells is extremely important in stem cell research. Creative Bioarray is committed to providing detailed data and comprehensive services for scientific research.

Adult stem cells provide a platform for different disease research or drug selection. The most common use of adult stem cells is MSC, which has basic functions in cell therapy, immunomodulation and gene therapy. Creative Bioarray can provide customers with stable and purified MSC lines and other adult stem cell lines in a short period of time to meet customer needs.

iPSC technology is a promising breakthrough in regenerative medicine. It was first proposed by Yamanaka in 2006. By reprogramming somatic cells such as fibroblasts and blood cells, iPSCs can be directly generated. Creative Bioarray provides customers with iPSC strains with high viability, which can be produced from different cell sources by globally recognized methods.

Creative Bioarray's advantages for stem cell lines generation services mainly include globally recognized advanced methods, stable and pure cell lines from reliable sources, service quality assurance, and detailed reports of experimental results.

"Creative Bioarray is an experienced and outstanding provider of stem cell research services. We are committed to providing detailed data and comprehensive services for your scientific research, and we are happy to use our rich experience and advanced platform to provide the best services to meet every customer's needs," said Hannah Cole, the marketing director of Creative Bioarray.

About Creative Bioarray

Founded in 2005, Creative Bioarray is dedicated to offering customers with innovative biotechnology products and services for research use to greatly enhance and drive innovation and standards in science. As a well-recognized industry leader with more than 10 years of experience and in-house experts supported, Creative Bioarray has already countenanced research all around the world.

Media Contact Company Name: Creative Bioarray Contact Person: Hannah Cole Email: Send Email Phone: 1-631-619-7922 Country: United States Website: https://www.creative-bioarray.com

More here:
Creative Bioarray Offers Stem Cell Lines Generation Service for Promoting Scientific Research - Press Release - Digital Journal

JSP191 With Low Dose Irradiation and Fludarabine is Safe and Effective for Patients with MRD+ AML/MDS – Cancer Network

By Adult Stem Cells

JSP191 combined with low dose total body irradiation (TBI) and fludarabine is a safe, well-tolerated treatment option capable of clearing minimal residual disease (MRD)positive acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in older adult patients undergoing nonmyeloablative allogeneic hematopoietic cell transplantation (HCT), according to a poster presented at the 2021 Transplantation and Cellular Therapy Meetings.

While the results of this phase 1 trial (NCT04429191) are early, the investigators emphasized that these data are the first to demonstrate that the antiCD117 monoclonal antibody is safe and effective in this disease cohort.

We are developing a first-in-class monoclonal antibody (mAb), JSP191, which targets and depletes normal and MDS/AML disease-initiating hematopoietic stem cells, wrote the investigators. JSP191 acts by inhibiting stem cell factor binding to CD117 present on HSC. We and others showed in pre-clinical models that HSC depletion can be enhanced by combining anti-CD117 mAb with low dose total body radiation.

The anti-CD117 monoclonal antibody was administered to a total of 6 patients intravenously at a dose of 0.6 mg/kg. Of note, the study population consisted of patients aged 60 years or older with MRD detected via cytogenetics, difference from normal flow cytometry, or next-generation sequencing (NGS).

The dual primary end points of the study are the safety and tolerability of JSP191 combined with low dose total body radiation and fludarabine and of JSP191 pharmacokinetics. The secondary end points include engraftment and donor chimerism, MRD clearance, event-free survival, and overall survival, among others.

The team used serum concentration of JSP191 determined by pharmacokinetics to establish the predicted JSP191 clearance and safety for the administration of fludarabine at 30 mg/m2 per day for 3 days, at days 4, -3, and -2 leading up to transplant.

At 28 days following transplant, 5 out of 6 patients showed signs of complete (>95%) donor CD15 myeloid chimerism in the peripheral blood.

To this point, there has been no evidence of significant infusion toxicities or JSP191-related serious adverse events. Also, a reduction or elimination of MRD in all subjects was seen at 28 days following transplant.

The research team explained that blood stem cell transplantation may offer the only curative therapy for many forms of both AML and MDS. Even though the current standard-of-care conditioning regimens administered before blood stem cell transplantation are well tolerated, they remain associated with increased relapse rates due to the prevalence of disease-causing hematopoietic stem cells and inadequate graft versus leukemia effect.

Further accrual for this study continues, while correlative analyses focusing on JPS191s impact with disease-initiating hematopoietic stem cells are ongoing.

References:

Muffly L, Kwon HS, Chin M, et al. Phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with low dose irradiation and fludarabine in older adults with MRD-positive AML/MDS undergoing allogeneic HCT. Presented at the 2021 Transplantation and Cellular Therapy Meetings, held February 8-12, 2021. Abstract LBA5.

Read more here:
JSP191 With Low Dose Irradiation and Fludarabine is Safe and Effective for Patients with MRD+ AML/MDS - Cancer Network

JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS – Targeted Oncology

By Adult Stem Cells

In older adult patients undergoing nonmyeloablative allogeneic hematopoietic cell transplantation (HCT), treatment with JSP191 combined with low dose total body irradiation (TBI) and fludarabine appears safe, well-tolerated treatment option capable of clearing minimal residual disease (MRD)positivity, according to a poster presented during the 2021 Transplantation and Cellular Therapy Meetings.

While the results of this phase 1 trial (NCT04429191) are early, the investigators emphasized that these data are the first to demonstrate that the antiCD117 monoclonal antibody is safe and effective in this disease cohort.

We are developing a first-in-class monoclonal antibody (mAb), JSP191, which targets and depletes normal and MDS/AML disease-initiating hematopoietic stem cells, wrote the investigators. JSP191 acts by inhibiting stem cell factor binding to CD117 present on HSC. We and others showed in pre-clinical models that HSC depletion can be enhanced by combining anti-CD117 mAb with low dose total body radiation.

The anti-CD117 monoclonal antibody was administered to a total of 6 patients intravenously at a dose of 0.6 mg/kg. Of note, the study population consisted of patients aged 60 years or older with MRD detected via cytogenetics, difference from normal flow cytometry, or next-generation sequencing (NGS).

The dual primary end points of the study are the safety and tolerability of JSP191 combined with low dose total body radiation and fludarabine and of JSP191 pharmacokinetics. The secondary end points include engraftment and donor chimerism, MRD clearance, event-free survival, and overall survival, among others.

The team used serum concentration of JSP191 determined by pharmacokinetics to establish the predicted JSP191 clearance and safety for the administration of fludarabine at 30 mg/m2 per day for 3 days, at days 4, -3, and -2 leading up to transplant.

At 28 days following transplant, 5 out of 6 patients showed signs of complete (>95%) donor CD15 myeloid chimerism in the peripheral blood.

To this point, there has been no evidence of significant infusion toxicities or JSP191-related serious adverse events. Also, a reduction or elimination of MRD in all subjects was seen at 28 days following transplant.

The research team explained that blood stem cell transplantation may offer the only curative therapy for many forms of both AML and MDS. Even though the current standard-of-care conditioning regimens administered before blood stem cell transplantation are well tolerated, they remain associated with increased relapse rates due to the prevalence of disease-causing hematopoietic stem cells and inadequate graft versus leukemia effect.

Further accrual for this study continues, while correlative analyses focusing on JPS191s impact with disease-initiating hematopoietic stem cells are ongoing.

References:

Muffly L, Kwon HS, Chin M, et al. Phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with low dose irradiation and fludarabine in older adults with MRD-positive AML/MDS undergoing allogeneic HCT. Presented at the 2021 Transplantation and Cellular Therapy Meetings, held February 8-12, 2021. Abstract LBA5.

Read the original post:
JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS - Targeted Oncology

Human Embryonic Stem Cells Market Analysis By Growth …

By Embryonic Stem Cells

The MarketWatch News Department was not involved in the creation of this content.

Japan, Japan, Tue, 09 Feb 2021 02:20:38 / Comserve Inc. / -- The report analyzes the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunity, and key regions development status.

The government funding for the development of regenerative medicine has been increasing in most developed countries, because of its applications in organ transplantation, tissue engineering, and various other applications. In the United States, two major government agencies, National Institutes of Health (NIH) and California Institute of Regenerative Medicine (CIRM), fund almost all the translational researches and regenerative medicine development in the country. It is estimated that the United States government invests around USD 800-900 million every year in stem cell research. Additionally, other factors such as the high prevalence of cardiac and malignant diseases, and rising demand for regenerative medicines are expected to drive the market.

Key Market Trends

Stem Cell Biology Research Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing. Stem cell biology research will show better growth, owing to the high prevalence of cardiac and malignant diseases. An article published by the ISSCR (International Society for Stem Cell Research) reported that the stem cells hold potential for the treatment of Parkinson's disease in humans. Recently, one of the market players, International Stem Cell Corporation (ISCO), received the patent covering methods for generating HLA homozygous parthenogenetic human stem cell lines from unfertilized eggs. The patent was issued in Australia. Furthermore, to boost the pace of stem cell research, the government is providing funding opportunities to researchers. Thus, owing to these factors, the market studied is expected to witness a high growth rate over the forecast period.

Click Here to Download Sample Report >> https://www.sdki.jp/sample-request-81122

North America Dominates the Human Embryonic Stem Cells Market

The human embryonic stem cells market is expected to dominate in the North America region owing to extensive research activities, along with high burden of chronic diseases and genetic disorders in the region. The United States also shows a high incidence of other diseases, such as diabetes, heart disease, renal failure, and osteoporosis. Human embryonic stem cells have high potential for use in treatment and may become a standard of care for these diseases. Additionally, the FDA has approved clinical trials, which indicated the use of stem cells. Hence, these factors are expected to influence the growth of the human embryonic stem cells market over the forecast period.

Competitive Landscape

The global players into the human embryonic stem cells market are Becton, Dickinson and Company, Cynata Therapeutics Limited, ESI BIO, Geron Corporation, International Stem Cell Corporation, Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc, Thermo Fisher Scientific and ViaCyte, Inc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format - Report customization as per the client's requirements - 3 months of analyst support

Request For Full Report >>https://www.sdki.jp/sample-request-81122

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 High Prevalence of Cardiac and Malignant Diseases 4.2.2 Rising Demand for Regenerative Medicines 4.2.3 Increasing Support from Governments and Government and Private Institutions 4.3 Market Restraints 4.3.1 High Cost of the Procedure 4.3.2 Stringent Regulatory Guidelines 4.4 Porter's Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Application 5.1.1 Regenerative Medicine 5.1.2 Stem Cell Biology Research 5.1.3 Tissue Engineering 5.1.4 Toxicology Testing 5.2 Geography 5.2.1 North America 5.2.1.1 United States 5.2.1.2 Canada 5.2.1.3 Mexico 5.2.2 Europe 5.2.2.1 Germany 5.2.2.2 United Kingdom 5.2.2.3 France 5.2.2.4 Italy 5.2.2.5 Spain 5.2.2.6 Rest of Europe 5.2.3 Asia-Pacific 5.2.3.1 China 5.2.3.2 Japan 5.2.3.3 India 5.2.3.4 Australia 5.2.3.5 South Korea 5.2.3.6 Rest of Asia-Pacific 5.2.4 Rest of World

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Becton, Dickinson and Company 6.1.2 Cynata Therapeutics Limited 6.1.3 ESI BIO 6.1.4 Geron Corporation 6.1.5 International Stem Cell Corporation 6.1.6 Merck KGaA 6.1.7 PromoCell GmbH 6.1.8 STEMCELL Technologies Inc 6.1.9 Thermo Fisher Scientific 6.1.10 ViaCyte, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Shibuya Data Count Email: sales@sdki.jp Tel: + 81 3 45720790

The post Human Embryonic Stem Cells Market Analysis By Growth, Emerging Trends , Future Opportunities and Forecast to 2025 appeared first on Comserveonline.

COMTEX_380504484/2652/2021-02-09T02:22:14

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.

Excerpt from:
Human Embryonic Stem Cells Market Analysis By Growth ...

Pros and Cons of embryonic stem cells – Pros an Cons

By Embryonic Stem Cells

Embryonic stem cells are cells that are found in living things and can regenerate and grow into other cells. This they do them by growing and repairing inside their host so long as the host is still living. These cells are known to be taken from 3-5 old embryos of blastocysts. Their major source is unfertilized in vitro eggs and they are acquired from donors who permit the cells to be used for research. These cells are crucial for they are used for many things. Some of the uses include; getting information on cell development and as an ingredient in the creation of drugs that cure diseases such as cardiovascular and diabetes.

Pros

1. considered lifeless: Many specialists argue that the embryos used for this research should not be viewed as persons. The reason being the embryos have not taken any human form that is they do not possess any physical and psychological properties that make them resemble a human being. Besides they also argue that the embryo has not been implanted in the uterus therefore cannot be regarded as human and the fact that their survival rate is very narrow and therefore they are not to be considered as living persons at any time.

2. Offer many medical possibilities: The stem cells are known to be undifferentiated that is they can be used in all parts of the body and can cure very many diseases. Their ability to cure as many diseases results from the fact that the embryonic stem cells can be used to generate other cells.

3. Progress in cancer research: Specialists conclude that the embryonic stem cells are very similar to the cancer cells which makes it easy to study them. Besides, their study since they are the same as the cancerous cells will help in the development of cancer drugs and other treatments.

4. Easily available: Most of these embryos can be attained from specific in vitro fertilization clinic centers. Many types of research have been made possible due to the availability of embryonic stem cells.

5. Flexibility: The major advantage of embryonic stem cells is their ability to create many more cells. This is useful in the making of drugs as well as treatment of some illness and lastly best used in research to find medication for other diseases.

6. The central nervous system is not formed yet: The embryo at the time of harvest is around two weeks which means that the nervous system has not yet developed. It is at this stage too that specialists also cant tell if the embryo is to develop into a fetus. This justifies in a way that since these embryos do not have senses yet, that means it is okay to harvest them and use them for research.

7. Harvested from unused embryos: Consent from donors is the key to the harvesting of the stem cells. Some people may think its unethical because of using fertilized eggs but since consent is involved that outweighs that thought. This should be seen as an act of good faith since it is the usage of embryos that were to be disposed of to create medical treatments.

Cons

1. High rejection rates: Most of the already done tests with the embryonic stem cells show that some embryonic stem cell therapies have resulted in too many health problems. It has been proven that the cells have been rejected severely as some of them do not respond as intended. Some of these cells have caused major impacts such as causing tumors.

2. Difficult to obtain: A lot of things are required to ensure that the embryonic stem cells are obtained, some of these include the fact that one has to wait for the embryo to grow in culture and several other months for it to fully mature to the stage where now it can be used.

3. Uncertain long-term side effects: Most of the treatments done with the embryonic stem cells are risky in such a way that the specialists are not certain of any future risk and how dangerous they could be. At the moment only short term benefits are enjoyed and research to show the long term side effects are still underway.

4. Harvesting requires the death of an embryo: Obtaining any embryonic stem cell requires one to get rid of the life within an embryo. This has brought ethical issues of the obtaining process despite the advantage that is brought about by the research.

5. They are expensive to obtain: The process of obtaining the stem cells is very expensive as it is estimated that harvesting an embryonic stem cell may cost $2,000. The therapies also ae as costly and this is available for only people with the ability to afford the medical service.

6. Difficulty in differentiating specialized lines: The process used by specialists to create the embryonic stem cells is insufficient.

7. Causes tumors: This is brought about by the extraction of the embryonic stem cells of undifferentiated culture which are prepared for tissue transplantation. This also can lead to the development of cancerous cells.

8. Risk of female donors: Female donors who consent to give out their embryos risk getting sick. Most of the research done however has shown that most of the donors consent to giving out their embryos rather than see them being discarded.

In conclusion, embryonic stem cells have been used by scientists to research on possible medications of cancer since the cells resemble the cancerous cells. The generative property of these cells gives them their unique advantage over other types of stem cells. A lot of debates have been done due to the thought that an embryo is a living thing and using it for the experiment would be inhuman. This, however, has been countered by the fact that people voluntarily give consent for their embryos to be used and the uses for the cells are for improving humanity rather than causing damage.

Read the original:
Pros and Cons of embryonic stem cells - Pros an Cons

Worldwide Cell Therapy Industry to 2027 – Profiling Allosource, Medipost and Mesoblast Among Others – PRNewswire

By Embryonic Stem Cells

DUBLIN, Feb. 9, 2021 /PRNewswire/ -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global cell therapy market accounted for $7,754. 89 million in 2019, and is expected to reach $48,115. 40 million by 2027, registering a CAGR of 25. 6% from 2020 to 2027.

Cell therapy involves administration of somatic cell preparations for treatment of diseases or traumatic damages. Cell therapy aims to introduce new, healthy cells into a patient's body to replace diseased or missing ones.

This is attributed to the fact that specialized cells, such as brain cells, are difficult to obtain from human body. In addition, specialized cells typically have a limited ability to multiply, making it difficult to produce sufficient number of cells required for certain cell therapies. Some of these issues can be overcome through the use of stem cells. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures.

Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells. Development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. Furthermore, automation in adult stem cells and cord blood processing and storage are the key technological advancements that fuel growth of the market for cell therapy.

In addition, growth in aging patient population, The rise in cell therapy transplantations globally, and surge in disease awareness drive growth of the global cell therapy market. Furthermore, The rise in adoption of human cells over animal cells for cell therapeutics research, technological advancements in field of cell therapy, and increase in incidences of diseases such as cancer, cardiac abnormalities, and organ failure are the key factors that drive growth of the global market.

Moreover, implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict growth of the market. On the contrary, surge in number of regulations to promote stem cell therapy and increase in funds for research in developing countries are expected to offer lucrative opportunities to the market in the future.

The global cell therapy market is categorized on the basis of therapy type, therapeutic area, cell type, end user, and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutics, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others.

The global cell therapy market is categorized on the basis of therapy type, therapeutic, cell type, end user and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutic area, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. On the basis of cell type, it is segregated into stem cell therapy and non-stem cell type. On the basis of end user, it is segregated into hospital & clinics and academic & research institutes. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

Key Topics Covered:

Chapter 1: Introduction 1.1. Report Description 1.2. Key Benefits for Stakeholders 1.3. Key Market Segments 1.4. Research Methodology 1.4.1. Secondary Research 1.4.2. Primary Research 1.4.3. Analyst Tools & Models

Chapter 2: Executive Summary 2.1. Key Findings of the Study 2.2. Cxo Perspective

Chapter 3: Market Overview 3.1. Market Definition and Scope 3.2. Key Findings 3.2.1. Top Player Positioning 3.2.2. Top Investment Pockets 3.2.3. Top Winning Strategies 3.3. Porter's Five Forces Analysis 3.4. Impact Analysis 3.4.1. Drivers 3.4.1.1. Technological Advancements in the Field of Cell Therapy 3.4.1.2. The Rise in Number of Cell Therapy Clinical Studies 3.4.1.3. The Rise in Adoption of Regenerative Medicine 3.4.2. Restraint 3.4.2.1. Developing Stage and Pricing 3.4.3. Opportunity 3.4.3.1. High Growth Potential in Emerging Markets 3.5. Impact of Covid-19 on Cell Therapy Market

Chapter 4: Cell Therapy Market, by Cell Type 4.1. Overview 4.1.1. Market Size and Forecast 4.2. Stem Cell 4.2.1. Key Market Trends and Opportunities 4.2.2. Market Size and Forecast, by Region 4.2.3. Market Size and Forecast, by Type 4.2.3.1. Bone Marrow, Market Size and Forecast 4.2.3.2. Blood, Market Size and Forecast 4.2.3.3. Umbilical Cord-Derived, Market Size and Forecast 4.2.3.4. Adipose-Derived Stem Cell, Market Size and Forecast 4.2.3.5. Others (Placenta, and Nonspecific Cells), Market Size and Forecast 4.3. Non-Stem Cell 4.3.1. Key Market Trends and Opportunities 4.3.2. Market Size and Forecast, by Region

Chapter 5: Cell Therapy Market, by Therapy Type 5.1. Overview 5.1.1. Market Size and Forecast 5.2. Autologous 5.2.1. Key Market Trends and Opportunities 5.2.2. Market Size and Forecast, by Region 5.2.3. Market Analysis, by Country 5.3. Allogeneic 5.3.1. Key Market Trends and Opportunities 5.3.2. Market Size and Forecast, by Region 5.3.3. Market Analysis, by Country

Chapter 6: Cell Therapy Market, by Therapeutic Area 6.1. Overview 6.1.1. Market Size and Forecast 6.2. Malignancies 6.2.1. Market Size and Forecast, by Region 6.2.2. Market Analysis, by Country 6.3. Musculoskeletal Disorders 6.3.1. Market Size and Forecast, by Region 6.3.2. Market Analysis, by Country 6.4. Autoimmune Disorders 6.4.1. Market Size and Forecast, by Region 6.4.2. Market Analysis, by Country 6.5. Dermatology 6.5.1. Market Size and Forecast, by Region 6.5.2. Market Analysis, by Country 6.6. Others 6.6.1. Market Size and Forecast, by Region 6.6.2. Market Analysis, by Country

Chapter 7: Cell Therapy Market, by End-user 7.1. Overview 7.1.1. Market Size and Forecast 7.2. Hospitals & Clinics 7.2.1. Key Market Trends and Opportunities 7.2.2. Market Size and Forecast, by Region 7.2.3. Market Analysis, by Country 7.3. Academic & Research Institutes 7.3.1. Key Market Trends and Opportunities 7.3.2. Market Size and Forecast, by Region 7.3.3. Market Analysis, by Country

Chapter 8: Cell Therapy Market, by Region 8.1. Overview 8.2. North America 8.3. Europe 8.4. Asia-Pacific 8.5. LAMEA

Chapter 9: Company Profiles 9.1. Allosource 9.1.1. Company Overview 9.1.2. Company Snapshot 9.1.3. Operating Business Segments 9.1.4. Product Portfolio 9.1.5. Key Strategic Moves and Developments 9.2. Cells for Cells 9.2.1. Company Overview 9.2.2. Company Snapshot 9.2.3. Operating Business Segments 9.2.4. Product Portfolio 9.3. Holostem Terapie Avanzate Srl 9.3.1. Company Overview 9.3.2. Company Snapshot 9.3.3. Operating Business Segments 9.3.4. Product Portfolio 9.4. Jcr Pharmaceuticals Co. Ltd. 9.4.1. Company Overview 9.4.2. Company Snapshot 9.4.3. Operating Business Segments 9.4.4. Product Portfolio 9.4.5. Business Performance 9.4.6. Key Strategic Moves and Developments 9.5. Kolon Tissuegene, Inc. 9.5.1. Company Overview 9.5.2. Company Snapshot 9.5.3. Operating Business Segments 9.5.4. Product Portfolio 9.5.5. Key Strategic Moves and Developments 9.6. Medipost Co. Ltd. 9.6.1. Company Overview 9.6.2. Company Snapshot 9.6.3. Operating Business Segments 9.6.4. Product Portfolio 9.6.5. Business Performance 9.7. Mesoblast Ltd 9.7.1. Company Overview 9.7.2. Company Snapshot 9.7.3. Operating Business Segments 9.7.4. Product Portfolio 9.7.5. Business Performance 9.8. Nuvasive, Inc. 9.8.1. Company Overview 9.8.2. Company Snapshot 9.8.3. Operating Business Segments 9.8.4. Product Portfolio 9.8.5. Business Performance 9.9. Osiris Therapeutics, Inc. 9.9.1. Company Overview 9.9.2. Company Snapshot 9.9.3. Operating Business Segments 9.9.4. Product Portfolio 9.10. Stemedica Cell Technologies, Inc. 9.10.1. Company Overview 9.10.2. Company Snapshot 9.10.3. Operating Business Segments 9.10.4. Product Portfolio

For more information about this report visit https://www.researchandmarkets.com/r/shw12n

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

More here:
Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others - PRNewswire

→←